Literature DB >> 17277738

FOXL2 mutations in Chinese patients with blepharophimosis-ptosis-epicanthus inversus syndrome.

Juan Wang1, Jinling Liu, Qingjiong Zhang.   

Abstract

PURPOSE: Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) is an autosomal dominant disorder where eyelid malformation associated with (type I) or without (type II) premature ovarian failure (POF). It is ascribed to mutations in the forkhead transcriptional factor2 (FOXL2) gene. The purpose of this study is to identify mutations in FOXL2 of Chinese patients with BPES.
METHODS: Genomic DNA was prepared from leucocytes of peripheral venous blood. The coding regions and nearby intron sequences of FOXL2 were analyzed by cycle and cloning sequencing.
RESULTS: Four mutations in FOXL2 were identified in six families, including c.241T>C, c.650C>G, c.804dupC, and c.672_701dup. Of the four, the c.241T>C and c.650C>G were novel and would result in missense changes of the encoded proteins, i.e., p.Tyr81His and p.Ser217Cys, respectively. The c.672_701dup (p.Ala224_Ala234dup) was detected in three families, indicating a mutation hotspot. The c.804dupC (p.Gly269ArgfsX265) mutation was found in one family.
CONCLUSIONS: Our results expand the spectrum of FOXL2 mutations and confirm the mutation hotspot in FOXL2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17277738      PMCID: PMC2533039     

Source DB:  PubMed          Journal:  Mol Vis        ISSN: 1090-0535            Impact factor:   2.367


  29 in total

1.  Mutations in FOXL2 underlying BPES (types 1 and 2) in Colombian families.

Authors:  J L Ramírez-Castro; N Pineda-Trujillo; A V Valencia; C M Muñetón; O Botero; O Trujillo; G Vásquez; B E Mora; N Durango; G Bedoya; A Ruiz-Linares
Journal:  Am J Med Genet       Date:  2002-11-15

Review 2.  Forkhead transcription factors: key players in development and metabolism.

Authors:  Peter Carlsson; Margit Mahlapuu
Journal:  Dev Biol       Date:  2002-10-01       Impact factor: 3.582

3.  A novel mutation in the FOXL2 gene in a patient with blepharophimosis syndrome: differential role of the polyalanine tract in the development of the ovary and the eyelid.

Authors:  Kenjiro Kosaki; Tsutomu Ogata; Rika Kosaki; Seiji Sato; Nobutake Matsuo
Journal:  Ophthalmic Genet       Date:  2002-03       Impact factor: 1.803

4.  Spectrum of FOXL2 gene mutations in blepharophimosis-ptosis-epicanthus inversus (BPES) families demonstrates a genotype--phenotype correlation.

Authors:  E De Baere; M J Dixon; K W Small; E W Jabs; B P Leroy; K Devriendt; Y Gillerot; G Mortier; F Meire; L Van Maldergem; W Courtens; H Hjalgrim; S Huang; I Liebaers; N Van Regemorter; P Touraine; V Praphanphoj; A Verloes; N Udar; V Yellore; M Chalukya; S Yelchits; A De Paepe; F Kuttenn; M Fellous; R Veitia; L Messiaen
Journal:  Hum Mol Genet       Date:  2001-07-15       Impact factor: 6.150

5.  Two families with blepharophimosis/ptosis/epicanthus inversus syndrome have mutations in the putative forkhead transcription factor FOXL2.

Authors:  R Bell; V A Murday; M A Patton; S Jeffery
Journal:  Genet Test       Date:  2001

6.  Identification of novel mutations in FOXL2 associated with premature ovarian failure.

Authors:  S E Harris; A L Chand; I M Winship; K Gersak; K Aittomäki; A N Shelling
Journal:  Mol Hum Reprod       Date:  2002-08       Impact factor: 4.025

7.  FOXL2-mutations in blepharophimosis-ptosis-epicanthus inversus syndrome (BPES); challenges for genetic counseling in female patients.

Authors:  Siv Fokstuen; Stylianos E Antonarakis; Jean-Louis Blouin
Journal:  Am J Med Genet A       Date:  2003-03-01       Impact factor: 2.802

8.  Sporadic and familial blepharophimosis -ptosis-epicanthus inversus syndrome: FOXL2 mutation screen and MRI study of the superior levator eyelid muscle.

Authors:  H Dollfus; C Stoetzel; S Riehm; W Lahlou Boukoffa; F Bediard Boulaneb; R Quillet; M Abu-Eid; C Speeg-Schatz; J J Francfort; J Flament; F Veillon; F Perrin-Schmitt
Journal:  Clin Genet       Date:  2003-02       Impact factor: 4.438

9.  FOXL2 and BPES: mutational hotspots, phenotypic variability, and revision of the genotype-phenotype correlation.

Authors:  Elfride De Baere; Diane Beysen; Christine Oley; Birgit Lorenz; Julie Cocquet; Paul De Sutter; Koen Devriendt; Michael Dixon; Marc Fellous; Jean-Pierre Fryns; Arturo Garza; Christoffer Jonsrud; Pasi A Koivisto; Amanda Krause; Bart P Leroy; Françoise Meire; Astrid Plomp; Lionel Van Maldergem; Anne De Paepe; Reiner Veitia; Ludwine Messiaen
Journal:  Am J Hum Genet       Date:  2003-01-14       Impact factor: 11.025

10.  The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome.

Authors:  L Crisponi; M Deiana; A Loi; F Chiappe; M Uda; P Amati; L Bisceglia; L Zelante; R Nagaraja; S Porcu; M S Ristaldi; R Marzella; M Rocchi; M Nicolino; A Lienhardt-Roussie; A Nivelon; A Verloes; D Schlessinger; P Gasparini; D Bonneau; A Cao; G Pilia
Journal:  Nat Genet       Date:  2001-02       Impact factor: 38.330

View more
  4 in total

1.  "Evaluation of four genes associated with primary ovarian insufficiency in a cohort of Mexican women".

Authors:  K J Juárez-Rendón; J E García-Ortiz
Journal:  J Assist Reprod Genet       Date:  2018-06-18       Impact factor: 3.412

2.  PAX3 mutations and clinical characteristics in Chinese patients with Waardenburg syndrome type 1.

Authors:  Juan Wang; Shiqiang Li; Xueshan Xiao; Panfeng Wang; Xiangming Guo; Qingjiong Zhang
Journal:  Mol Vis       Date:  2010-06-22       Impact factor: 2.367

3.  Identification of the forkhead transcriptional factor 2 (FOXL2) gene mutations in four Chinese families with blepharophimosis syndrome.

Authors:  Li Zhang; Liming Wang; Ruifang Han; Lifang Guan; Baohong Fan; Mingmei Liu; Ming Ying; Hao Peng; Ningdong Li
Journal:  Mol Vis       Date:  2013-11-16       Impact factor: 2.367

Review 4.  The Genetic and Clinical Features of FOXL2-Related Blepharophimosis, Ptosis and Epicanthus Inversus Syndrome.

Authors:  Cécile Méjécase; Chandni Nigam; Mariya Moosajee; John C Bladen
Journal:  Genes (Basel)       Date:  2021-03-04       Impact factor: 4.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.